1. Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).
- Author
-
Mousset S, Buchheidt D, Heinz W, Ruhnke M, Cornely OA, Egerer G, Krüger W, Link H, Neumann S, Ostermann H, Panse J, Penack O, Rieger C, Schmidt-Hieber M, Silling G, Südhoff T, Ullmann AJ, Wolf HH, Maschmeyer G, and Böhme A
- Subjects
- Amphotericin B administration & dosage, Amphotericin B adverse effects, Amphotericin B therapeutic use, Antifungal Agents administration & dosage, Antifungal Agents adverse effects, Candidiasis, Invasive drug therapy, Candidiasis, Invasive etiology, Catheter-Related Infections drug therapy, Catheter-Related Infections prevention & control, Chemotherapy-Induced Febrile Neutropenia complications, Clinical Trials as Topic, Combined Modality Therapy, Drug Monitoring, Drug Therapy, Combination, Echinocandins administration & dosage, Echinocandins adverse effects, Echinocandins therapeutic use, Fungemia drug therapy, Fungemia prevention & control, Humans, Immunocompromised Host, Immunotherapy, Invasive Pulmonary Aspergillosis drug therapy, Invasive Pulmonary Aspergillosis etiology, Invasive Pulmonary Aspergillosis surgery, Mycoses etiology, Mycoses surgery, Mycoses therapy, Salvage Therapy, Triazoles administration & dosage, Triazoles adverse effects, Triazoles therapeutic use, Antifungal Agents therapeutic use, Mycoses drug therapy, Neoplasms complications
- Abstract
The Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) here presents its updated recommendations for the treatment of documented fungal infections. Invasive fungal infections are a main cause of morbidity and mortality in cancer patients undergoing intensive chemotherapy regimens. In recent years, new antifungal agents have been licensed, and agents already approved have been studied in new indications. The choice of the most appropriate antifungal treatment depends on the fungal species suspected or identified, the patient's risk factors (e.g., length and depth of neutropenia), and the expected side effects. This guideline reviews the clinical studies that served as a basis for the following recommendations. All recommendations including the levels of evidence are summarized in tables to give the reader rapid access to the information.
- Published
- 2014
- Full Text
- View/download PDF